Home・Aandelen Lijst・Compugen Ltd

Compugen Ltd

Gesloten

2.39 4.37

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.39

Max

2.42

Belangrijke statistieken
By Trading Economics
Inkomsten	-65M -7.7M
Verkoop	-65M 2.2M
K/W Sectorgemiddelde	6.263 68.51
EPS	-0.07
Winstmarge	-352.436
Werknemers	75
EBITDA	-64M -7.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+107.47% upside

Dividenden
By Acuity
Volgende Winsten	9 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-45M 225M
Vorige openingsprijs	-1.98
Vorige sluitingsprijs	2.39

Compugen Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 aug 2026, 23:52 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower, reaching its lowest point in a month amid cautious market sentiment and correlated asset declines.

9 aug 2026, 23:51 UTC

Bitcoin and Ethereum decline amid bearish sentiment, while U.S. labor data sparks record highs in equity markets and lowers Fed rate hike expectations.

9 aug 2026, 23:51 UTC

Singapore's markets closed for National Day; Japan's BOJ releases opinions, while China's inflation and PPI growth fall short of expectations, raising economic stability concerns.

9 aug 2026, 23:51 UTC

U.S. equity markets rally as disappointing July jobs data lowers Fed rate hike expectations, while Bitcoin and Ethereum decline amid cautious investor sentiment.

9 aug 2026, 23:51 UTC

Singapore's markets closed for National Day; Japan's monetary policy remains unclear while China's inflation drops to 0.5%, raising deflation concerns.

9 aug 2026, 23:51 UTC

Retail Sales Ex Autos Expected to Rise 0.2% in July Amid Mixed Economic Signals

9 aug 2026, 23:51 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.5% Amid Mixed Market Sentiment and Geopolitical Concerns

9 aug 2026, 23:51 UTC

Japan's GDP Growth Forecasted at 0.02% for Q2 Amid Mixed Economic Sentiment and Global Uncertainties

9 aug 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading lower during the session, reflecting cautious market sentiment amid slight declines in Ethereum and minimal hedge fund re-grossing in AI themes.

9 aug 2026, 23:41 UTC

BoJ Summary of Opinions Release Expected to Clarify Interest Rate Outlook Amidst Mixed Market Sentiment and Global Economic Trends.

9 aug 2026, 23:41 UTC

Japan's June current account data expected to show a significant surplus decline, raising concerns about economic challenges and impacting financial markets.

9 aug 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.1% in August Amid Cautious Consumer Sentiment and Economic Uncertainty

9 aug 2026, 23:31 UTC

Market Awaits July 2026 PPI Release Amid Mixed Inflation Signals and Potential Deflationary Pressures.

9 aug 2026, 23:31 UTC

Correlated Moves

Cardano is declining in today's session, continuing a downward trend observed since Saturday. The asset's movement reflects broader bearish sentiment in the market.

9 aug 2026, 23:21 UTC

Core Producer Prices Expected to Rise 0.2% Amid Slower Inflation and Cautious Investor Sentiment Ahead of August Release

9 aug 2026, 23:01 UTC

Palladium is trading lower during Sunday’s session, despite earlier gains. The asset remains above its 20-day moving average and near a one-month high.

9 aug 2026, 23:01 UTC

Silver has been gaining since Friday's close, currently above its 20-day moving average. The asset reached a session high before pulling back slightly.

9 aug 2026, 23:01 UTC

Silver/CAD is trading higher since Friday's close, reflecting a cumulative return of 0.17%. The price remains above its 20-day moving average.

9 aug 2026, 23:01 UTC

Gold/SGD is trading roughly flat, remaining above its 20-day moving average and near the upper end of its one-month range.

9 aug 2026, 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, reflecting volatility earlier in the session. The asset remains above its 20-day moving average and near its one-month range's upper end.

9 aug 2026, 23:01 UTC

The US 2Y Treasury Bond Index is trading higher, remaining steady near the upper end of its one-month trading range. No specific news was identified.

9 aug 2026, 23:01 UTC

Correlated Moves

Gold/JPY is advancing, reflecting a positive trend since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

9 aug 2026, 23:01 UTC

Gold and silver are trading lower, continuing a downward trend since Friday's close. The assets briefly rebounded earlier in the session.

9 aug 2026, 23:01 UTC

Correlated Moves

Gold/GBP is trading roughly flat, influenced by a slight increase in Silver. Market sentiment remains cautious amid minimal hedge fund re-grossing within AI themes.

9 aug 2026, 23:01 UTC

Silver/NZD is higher today, maintaining a position above its 20-day moving average after pulling back from earlier session highs. No specific news was identified.

9 aug 2026, 23:01 UTC

Silver/JPY is trading higher today, maintaining a position above its 20-day moving average. The asset showed fluctuations earlier in the session.

9 aug 2026, 23:01 UTC

Silver/HKD is higher during Sunday’s session, continuing its positive momentum from Friday. The asset remains above its 20-day moving average.

9 aug 2026, 23:01 UTC

Correlated Moves

Gold/CHF is trading roughly flat, maintaining stability after a slight increase in correlation with silver amid cautious market sentiment and hedge fund activity.

9 aug 2026, 23:01 UTC

Silver/SGD is advancing during the ongoing session, remaining above its 20-day moving average and near the upper end of its one-month range.

9 aug 2026, 23:01 UTC

Gold/HKD is trading roughly flat, remaining 6.16% above its 20-day moving average and near the upper end of its one-month range.

Peer Vergelijking

Prijswijziging

Compugen Ltd Prognose

Koersdoel

By TipRanks

107.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD 107.47%

Hoogste 6 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compugen Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Compugen Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.